Andere Sprachen Arbutus Biopharma Corporation

Aktien

A14XMD

CA03879J1003

ABUS

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 26.04.2024			% 5 Tage	% 1. Jan.
2,73 ^USD	+0,37 %		+0,37 %	+9,20 %

05.04.	Arbutus Biopharma erhält günstigen Gerichtsbeschluss in Moderna-Patentklage	MT
04.04.	Moderna erleidet Rückschlag in Klage von Arbutus	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update	18.04.
Arbutus Biopharma : Corporate Presentation - April 2024	15.04.
Arbutus Biopharma Obtains Favorable Court Order in Moderna Patent Lawsuit	05.04.
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna	04.04.
Moderna Suffers Setback in Lawsuit by Arbutus	04.04.
Moderna shares fall after judge sides with Arbutus in patent fight	03.04.
Arbutus to Participate in Two Upcoming Investor Conferences	08.03.
Arbutus to Participate in Two Upcoming Investor Conferences	08.03.
Arbutus Biopharma Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update	01.03.
Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update	29.02.
Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update	29.02.
Arbutus Biopharma Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	29.02.
Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update	15.02.
Arbutus Announces 2024 Corporate Objectives and Provides Financial Update	08.01.
Arbutus Announces 2024 Corporate Objectives and Provides Financial Update	08.01.
Arbutus Biopharma, Inc. Announces Clinical Development Milestones to Advance Its HBV Pipeline	08.01.
Arbutus Biopharma Corporation and Barinthus Biotherapeutics plc Present Preliminary Data from Phase 2A Clinical Trial Combining Imdusiran with VTP-300 at AASLD	09.11.
Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®	09.11.
Arbutus to Present at Jefferies London Healthcare Conference	08.11.
Arbutus to Present at Jefferies London Healthcare Conference	08.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Arbutus Biopharma Corporation

Aktien

A14XMD

CA03879J1003

ABUS

Andere Sprachen

Filter